Carl J Fichtenbaum, Heather J Ribaudo, Jorge Leon-Cruz, Edgar T Overton, Markella V Zanni, Carlos D Malvestutto, Judith A Aberg, Emma M Kileel, Kathleen V Fitch, Marije Van Schalkwyk, Nagalingeswaran Kumarasamy, Esteban Martinez, Breno Riegel Santos, Yvetot Joseph, Janet Lo, Sue Siminski, Kathleen Melbourne, Craig A Sponseller, Patrice Desvigne-Nickens, Gerald S Bloomfield, Judith S Currier, Udo Hoffmann, Pamela S Douglas, Steven K Grinspoon
BACKGROUND: Patterns of antiretroviral therapy (ART) use and immunologic correlates vary globally, and contemporary trends are not well described. METHODS: The REPRIEVE trial (Randomized Trial to Prevent Vascular Events in HIV) enrolled persons with human immunodeficiency virus (HIV) who were aged 40-75 years, receiving ART, and had low-to-moderate cardiovascular disease risk. ART use was summarized within Global Burden of Disease (GBD) super-regions, with adjusted linear and logistic regression analyses examining associations with immune parameters and key demographics...
July 9, 2020: Journal of Infectious Diseases